Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Cellceutix, a preclinical cancer, anti-inflammatory and autism drug developer, has been issued notice of acceptance to initiate Kevetrin clinical trial.
Subscribe to our email newsletter
Discovered by the founder of Cellceutix, Krishna Menon, Kevetrin is small molecule compound which has showed anti-cancer activity against cancer cell lines.
Cellceutix CEO Leo Ehrlich said their research to date on Kevetrin has been stellar and the approval to conduct their clinical trials adds a great deal of validation to their beliefs that Kevetrin could be one of the prominent cancer compounds known at this time.
"Additional details will be coming upon finalization of review and signed contracts," Ehrlich said.